Amgen 3Q Revenues: $3.9 billion (+7%) 3Q Earnings: $1.2 billion (earnings were $201 million in 3Q07) YTD Revenues: $11.3 billion (+3%) YTD Earnings: $3.2 billion (+39%) Comments: Sales of Aranesp were up 3% to $845 million. Sales of Epogen increased 5% to $634 million. Combined sales of Neulasta and Neupogen were up 8% to $1.2 billion. Sales of Enbrel were $893 million (+9%). Sales of Sensipar increased 32% to $161 million. R&D expenses were $729 million in the quarter (-6%). ...